Abstract
Background: Astroglioma, one major form of brain tumors, has remained principally tough to handle for decades, due to the complexity of tumor pathology and the poor response to chemo- and radio-therapies.
Methods: Our previous study demonstrated that nifurtimox could regulate the signaling axis of AKT-GSK3β in various tumor types including the astroglioma U251 cells. Intriguingly, earlier case studies suggested that nifurtimox could possibly permeate the blood brain barrier and arrest neuroblastoma in the brain. These observations jointly encouraged us to explore whether nifurtimox would hinder the growth of astroglioma in vivo.
Results: Our results exhibited that nifurtimox could competently hinder the development of astroglioma in the mouse brain as compared to temozolomide, the first line of drug for brain tumors. Meanwhile the surviving rate, as well as the body-weight was dramatically upregulated upon nifurtimox treatment, as compared to that of temozolomide. These findings offered nifurtimox as a better alternative drug in treating astroglioma in vivo.
Conclusion: Persistently, the manipulation of the signaling axis of AKT-GSK3β in astroglioma was found in line with earlier findings in neuroblastoma when treated with nifurtimox.
Keywords: Astroglioma, Nifurtimox treatment, Temozolomide, in vivo, AKT-GSK3β, blood brain barrier.
Current Molecular Medicine
Title:Nifurtimox Hampered the Progression of Astroglioma In vivo Via Manipulating the AKT-GSK3β axis
Volume: 20 Issue: 9
Author(s): Qiuxia Zhang, Zhenshuai Chen, Wei Yuan, Yu-Qing Tang, Jiangli Zhu, Wentao Wu, Hongguang Ren, Hui Wang, Weiyi Zheng, Zhongjian Zhang*Eryan Kong*
Affiliation:
- Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang,China
- Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang,China
Keywords: Astroglioma, Nifurtimox treatment, Temozolomide, in vivo, AKT-GSK3β, blood brain barrier.
Abstract:
Background: Astroglioma, one major form of brain tumors, has remained principally tough to handle for decades, due to the complexity of tumor pathology and the poor response to chemo- and radio-therapies.
Methods: Our previous study demonstrated that nifurtimox could regulate the signaling axis of AKT-GSK3β in various tumor types including the astroglioma U251 cells. Intriguingly, earlier case studies suggested that nifurtimox could possibly permeate the blood brain barrier and arrest neuroblastoma in the brain. These observations jointly encouraged us to explore whether nifurtimox would hinder the growth of astroglioma in vivo.
Results: Our results exhibited that nifurtimox could competently hinder the development of astroglioma in the mouse brain as compared to temozolomide, the first line of drug for brain tumors. Meanwhile the surviving rate, as well as the body-weight was dramatically upregulated upon nifurtimox treatment, as compared to that of temozolomide. These findings offered nifurtimox as a better alternative drug in treating astroglioma in vivo.
Conclusion: Persistently, the manipulation of the signaling axis of AKT-GSK3β in astroglioma was found in line with earlier findings in neuroblastoma when treated with nifurtimox.
Export Options
About this article
Cite this article as:
Zhang Qiuxia , Chen Zhenshuai , Yuan Wei , Tang Yu-Qing, Zhu Jiangli , Wu Wentao , Ren Hongguang , Wang Hui , Zheng Weiyi , Zhang Zhongjian *, Kong Eryan *, Nifurtimox Hampered the Progression of Astroglioma In vivo Via Manipulating the AKT-GSK3β axis, Current Molecular Medicine 2020; 20 (9) . https://dx.doi.org/10.2174/1566524020666200409124258
DOI https://dx.doi.org/10.2174/1566524020666200409124258 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies
Current Cancer Drug Targets Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Current Neuropharmacology Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease
Current Alzheimer Research A Survey and a Molecular Dynamics Study on the (Central) Hydrophobic Region of Prion Proteins
Current Pharmaceutical Biotechnology Undesired Neural Side-Effects of a Drug, a Chemical and Genetic Interrelated Problem
Central Nervous System Agents in Medicinal Chemistry Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Nucleo-Cytoplasmic Transport of Proteins as a Target for Therapeutic Drugs
Current Medicinal Chemistry Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Mitochondrial Superoxide Dismutase: A Promising Target for New Anticancer Therapies
Current Medicinal Chemistry